Formulation for inhalation
November 2, 2019. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent ReferencesComposition Micronized aerosol steroids Dosage inhalator Dosage inhalator Inhalation pharmaceuticals Device Low flow rate nebulizer apparatus and method of nebulization Non-chlorofluorocarbon aerosol formulations Process for forming medicament carrier for dry powder inhalator Medicament inhalation device and formulation InventorAssigneeApplicationNo. 431916 filed on 11/02/1999US Classes:424/46, Powder or dust containing514/171, With additional active ingredient514/174, -O-C-O- is part of a hetero ring (e.g., acetonide, etc.)514/653, Hydroxy, bonded directly to carbon, attached directly or indirectly to the acyclic carbon or chain by acyclic nonionic bonding (e.g., beta hydroxy phenethylamines, etc.)514/826ASTHMAExaminersPrimary: Weddington, Kevin E.Attorney, Agent or FirmForeign Patent References
International ClassesA61K 009/14A61K 031/56 A61K 031/58 A61K 031/135 Foreign Application Priority Data1998-01-09 SEAbstractA dry powder composition comprising one more potent pharmaceutically active substances and a carrier substance, all of which are in finely divided form, wherein the formulation has a poured bulk density of from 0.28 to 0.38 g/ml is useful in the treatment of respiratory disorders.Field of SearchPowder or dust containingWith additional active ingredient -O-C-O- is part of a hetero ring (e.g., acetonide, etc.) Hydroxy, bonded directly to carbon, attached directly or indirectly to the acyclic carbon or chain by acyclic nonionic bonding (e.g., beta hydroxy phenethylamines, etc.) ASTHMA | |
